Eye care was barely a blip on the radar at AbbVie Inc. when it acquired Allergan plc – a 2016 label expansion of top-seller Humira (adalimumab) into uveitis was AbbVie’s only foray into ophthalmic medicine before the mega-merger that happened to bring it into the sector. Eye care R&D and product performance still may not be a central topic during AbbVie’s quarterly earnings calls, but the recent approval of Vuity for presbyopia represents progress for the combined company’s burgeoning eye care segment.
During its third quarter earnings call on 29 October, AbbVie noted that its eye care franchise – led by dry...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?